Recessive Dystrophic Epidermolysis Bullosa

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
1
PTR-01Phase 21 trial
Active Trials
NCT05143190Completed2Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BridgeBio PharmaPTR-01

Clinical Trials (1)

Total enrollment: 2 patients across 1 trials

NCT05143190BridgeBio PharmaPTR-01

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Start: Dec 2021Est. completion: Aug 20222 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space